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esponsibility of Xi’Abstract An RP-HPLC method for the simultaneous determination of Ramipril (RP) and Amlodipine (AL)
in tablets was developed and validated by Chinese Pharmacopoeia 2010. The linearity of the proposed
method was investigated in the range of 0.01–0.25 mg/mL (r2¼0.9998) for RP and 0.014–0.36 mg/mL
(r2¼0.9997) for AL. The limits of detection (LOD) were 0.06 μg/mL and 0.02 μg/mL for RP and AL, and
the limits of quantitation (LOQ) were 0.2 μg/mL and 0.07 μg/mL, respectively. Some major impurities
and degradation products did not disturb the detection of RP and AL and the assay can thus be considered
stability-indicating.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ramipril (RP), with the chemical name [(2S, 3aS, 6aS)-1-[(S)-2-
[[(S)-1-(ethoxycarbonyl)-3-phenylpropyl] amino] propanoyl] octa-
hydrocyclopenta [b] pyrrole-2-carboxylic acid (Fig. 1I)], is an
angiotensin-converting enzyme inhibitor (ACEI), which is widely




an Jiaotong University.RP plays an important role in inhibiting the conversion of the inactive
angiotensin I to the active angiotensin II. However, it may cause
hypotension, cough and other side effects [1–3].
Amlodipine (AL), [3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)
methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dic-
arboxylate (Fig. 1VI)], is a long-acting dihydropyridine calcium
channel blocker (CCB) with dose-related antihypertensive efﬁ-
cacy. It inhibits calcium ions to be transported into vascular
smooth muscle and cardiac muscle to protect the target organs. But
it would also cause peripheral edema as a side effect. It is always
used in the treatment of hypertension and angina [4–6].
Either RP or AL is a good choice for the treatment of hypertension.
But in fact, a large majority of hypertensives ultimately require drug
combination to decrease the damage of heart, brain, kidney, etc. Fixed-
dose combinations of drugs with complementary properties offer thevier B.V. All rights reserved.
Fig. 1 Chemical structures of Ramipril (I), Ramipril impurities A (II), B (III), C (IV), D (V), Amlodipine (VI), and Amlodipine impurity D (VII).
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ness, as well as the compliance [7]. The combination therapy of ACEI
and CCB has been proved to be effective [8–10]. So the combination
of RP and AL would also be a good therapeutic option.
There are many reported methods to determine either RP [11–13] or
AL [14–17] alone or in combination with other drugs [18–22] in
dosage forms. But to the best of our knowledge, none has been
reported the simultaneous determination of RP and AL in the presence
of the degradants and the ﬁve major impurities (Ramipril impurity A
(Fig. 1II), B (Fig. 1III), C (Fig. 1IV), D (Fig. 1V) and Amlodipine
impurity D (Fig. 1VII)). This paper aims to describe the development
and validation of the HPLC method for the simultaneous determination
of RP and AL in the same tablet dosage forms.2. Materials and methods
2.1. Chemicals and reagents
RP active pharmaceutical ingredient (API) was obtained from the
Green Syn Co., Ltd. (Guangzhou, China), and AL besylate API
was from the Weihai Disu Pharmc Co., Ltd. (Weihai, China).
Compound Ramipril and Amlodipine besylate tablets (each tablet
containing 2.5 mg of RP and 5 mg of AL besylate) and the tabletexcipients were kindly supplied by Chengdu Haisco Pharmaceu-
tical Co., Ltd. (Chengdu, China).
The reference standard of AL besylate was purchased from the
National Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China). The RP reference standard, impurity
standards of RP and AL were procured by European Directorate
for the Quality of Medicines of European Council.
HPLC-grade acetonitrile was obtained from Honeywell (USA).
HPLC-grade triethylamine was obtained from Kermel chemical
reagents company (Tianjin, China). Water was prepared by ultra
pure water system (UPA, Chongqing, China). All the other used
reagents were of analytical grade.2.2. HPLC instruments and analytical conditions
Chromatographic separation was achieved by using a Shimadzu
model 20A liquid chromatographic system (Tokyo, Japan),
equipped with a 20AT pump and a PDA detector (SPD-20A).
The system was controlled by a system controller (SCL-20A) and
a personal computer.
The chromatographic column utilized in these studies was an Inertsil
ODS-3 column (250 mm 4.0 mm, 3 μm). A 10 mm 4.0 mm (i.d.)
guard column packed with 5 mm diameter Inertsil ODS-3 packing was
also utilized. The column temperature was maintained at 55 1C.
S.-Y. Dai et al.442The mobile phase A consisted of 60 mM sodium perchlorate buffer
(containing 7.2 mM triethylamine)-acetonitrile (60:40, v/v) and mobile
phase B was 60 mM sodium perchlorate buffer (containing 7.2 mM
triethylamine)-acetonitrile (20:80, v/v). The apparent pH of the mobile
phases was adjusted to 2.6 with phosphoric acid. The gradient program
used is given in Table 1. The ﬂow rate was 1.0 mL/min and the
injection volume was 20 mL.
The spectra were obtained from the PDA detector. Peak purity
analysis was carried out over a wavelength range of 190–350 nm by
using the Shimadzu LC-solution software. The detection wavelength
was set at 210 nm because all the components had higher responses.2.3. Solutions and sample preparation
For the system suitability test, the solution containing 0.1 mg/mL
of RP, 0.2 mg/mL of AL besylate and each 0.1 mg/mL of ﬁve
major impurities was prepared by mobile phase A. For the linearity
studies, a standard stock solution containing 0.25 mg/mL of RP
and 0.5 mg/mL of AL besylate (equivalent to approximately
0.36 mg/mL of the free base) was prepared by mobile phase A
and diluted with the same solvent to yield solutions at different
concentrations. These solutions were protected from light using
aluminum foil and stored at 4 1C in the refrigerator.
The test sample solution was prepared from 20 pulverized
compound RPAL tablets. A 10-tablet equivalent mass correspond-
ing to 25 mg RP and 50 mg AL besylate was weighed into a
250 mL volumetric ﬂask, and mobile phase A was added to the
volume. After ultrasonicated for 15 min, the mixture was centri-
fuged at 10,000 rpm for 10 min. The supernatant was separated
and transferred into the HPLC instrument to be analyzed.
Samples were subjected to stress conditions of light, heat, acid,
base and oxidation in order to evaluate the ability of the proposed
method to separate RP and AL from both known and unknown
degradation products. In the stress studies, all the solutions were
prepared by weighing 4-tablet equivalent mass of sample powders
containing about 10 mg RP and 20 mg AL besylate into 10 mL
volumetric ﬂasks, or by weighing 10 mg RP or 20 mg AL besylate
pure API. Acid degradation was conducted using 2 mL of 0.1 M
hydrochloric acid, and alkali degradation was carried out in 2 mL
of 0.1 M sodium hydroxide. The stressed solutions were kept in
water bath for 5 min, neutralized and then diluted by mobile phase
A. Oxidation degradation was performed by adding 2 mL of 3%
H2O2 and kept in water bath for 5 min, and then diluted with
mobile phase A. For the temperature stress study, compoundTable 1 Gradient program proposed for the analysis of AL








0–10 100 0 Isocratic
10–15 100-60 0-40 Linear ramp to
40% B
15–20 60 40 Isocratic
20–25 60-30 40-70 Linear ramp to
70% B
25–35 30 70 Isocratic
35–40 30-100 70-0 Linear ramp to
100% A
40–55 100 0 IsocraticRPAL tablets, RP and AL besylate API were exposed to dry heat
of 60 1C in a convection oven for 10 days. For photo stability
studies, compound RPAL tablets, RP and AL besylate API were
exposed to 4500 lx light in a light cabinet for 10 days. After
degradation, these stressed tablets were removed, crushed and
mixed. Then the powers were dissolved and extracted with 10 mL
mobile phase A for further analysis. Ten microgram RP or 20 mg
AL besylate API were also resolved in 10 mL mobile phase A to
study the origination of related substances.3. Results and discussion
3.1. Method development
A gradient HPLC method was adopted to get a shorter runtime and
higher sensitivity due to the polarity differences among RP, AL
and their related impurities. And also considering the stability of
the system, the related substances test method of RP described in
the European Pharmacopoeia (Ph. Eur.)[23] was used as the
starting point for further development. A stainless steel column
(250 mm 4.0 mm, 3 mm) was used in the ofﬁcial Ph. Eur.
method. The mobile phases A and B all consisted of acetonitrile,
sodium perchlorate buffer and 1 mL triethylamine with different pH
values adjusted to 3.6 and 2.6 with phosphoric acid, respectively. But
to our study, RP and AL could not be separated well and the peaks
with bad symmetries were also observed under this condition.
As RP and AL had N–H groups as basic nitrogen centers, the
amount of perchlorate and the pH of mobile phase would affect the
peak shape, resolution and symmetry, since perchlorate plays as
ion-pair reagent and the pH would affect the protonation reactions.
So the amount of perchlorate and the pH of mobile phases should
be adapted. The results showed that the retention times of RP and
AL were lengthened when the amount of perchlorate was
increased. The retention time of RP would be shortened while
the retention time of AL had no signiﬁcant change when the pH
was decreased. The amount of triethylamine used as a tailing-
suppressing reagent was not investigated as it was unnecessary to
change when the amount of perchlorate and the pH of mobile
phase were appropriate. The ratios of mobile phase A and B,
various gradient programs were also tried to get better resolution
and shorter separation time. After a lot of work, the amount of
sodium perchlorate, the pH and ratios of mobile phases given in
Section 2.2 and the gradient program presented in Table 1 were
found to give symmetric peak, higher column performance, shorter
running time and good resolution among the main components and
the related substances.
The column diameter of 5 mm was also investigated but with a
worse column performance. So the column diameter of 3 mm was
chosen. Besides above consideration, the column temperature was
also studied. The column temperatures of 60 1C, 55 1C and 50 1C
were studied and 55 1C was ﬁnally chosen by considering the
working life of the column as well as the pressure and stability of
the system. Typical chromatograms obtained with the ﬁnal
condition are shown in Fig. 2.
As seen from the chromatogram, the method was capable of
separating RP, AL and the 12 related substances. Peak numbered 1
was identiﬁed as benzene sulfonic acid. Peaks 4, 6, 8 and 11 were
identiﬁed and correspond to Amlodipine impurity D, Ramipril
impurity B, C and D by comparing the relative retention time
(RRT) with the available reference impurities. Other peaks that
Fig. 2 Chromatograms of sample solution (1 mg/mL RP and 2 mg/mL AL solution using the ﬁnal optimized mehtod). 1. Benzene sulfonic acid,
2. Unknown 1, 3. Unknown 2, 4. Amlodipine impurity D, 5. Unknown 3, 6. Ramipril impurity B, 7. Unknown 4, 8. Ramipril impurity C,
9. Unknown 5, 10. Unknown 6, 11. Ramipril impurity D, 12. Unknown 7, and 13. Unknown 8.
Fig. 3 Chromatogram of the system suitability test solution. 1. Benzene sulfonic acid, 2. Ramipril impurity A, 3. Amlodipine impurity D,
4. Ramipril impurity B, 5. Ramipril impurity C, and 6. Ramipril impurity D.
Fig. 4 Chromatogram of the tablet excipients.
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at 0.1%.3.2. Method validation
The proposed method was validated with the aspect of system
suitability test, speciﬁcity, linearity and range, accuracy, precision,
LOD, LOQ, stability and robustness according to the Chinese
Pharmacopoeia Volume II requirements [24].3.2.1. System suitability test
System suitability was determined by six replicate injections of the
system suitability solution. The acceptance criteria were less than
2% relative standard deviation (RSD) for peak areas, greater than
3000 column plates, less than 1.5 of the USP tailing factor, and
greater than 1.5 of the resolution. The results obtained were all within
the acceptable limits. The resolutions among RP, AL and the closest
eluting peaks were bigger than 2 which indicated that this method was
reliable for the quantiﬁcation of RP and AL. A typical chromatogram
for the system suitability test is shown in Fig. 3.
S.-Y. Dai et al.4443.2.2. Speciﬁcity
The selectivity of the method was conﬁrmed by observing
potential interferences caused by excipients of tablet formulations
and degradation products under stress conditions as indicated by
ICH [25].
The chromatogram of the tablet excipients (Fig. 4) shows that there
were no interference of peaks to the determination of RP and AL.
All stressed samples were compared with an un-stressed sample
solution. The proposed chromatographic conditions were found to
be speciﬁc under all applied stress conditions, which was visiblyFig. 5 Chromatograms of stress test. (A) Acid hydrolysis-degraded table
tablet powder; (D) photo degraded tablet powder; (E) oxidation degraded ta
(Amlodipine) besylate API (the peak number is the same as in Fig. 2).conﬁrmed in Fig. 5. The peak purity indices for RP and AL in
stressed solutions were found to be better (purity angleopurity
threshold) indicating that no additional peaks were co-eluting with
the analytes. And they also evidenced the ability of the method to
assess unequivocally the analytes of interest in the presence of
potential interference.
3.2.3. Origination of related substances
The origination of the related substances in tablets was investi-
gated. As can be seen from the chromatograms of RP and ALt powder; (B) base hydrolysis-degraded tablet powder; (C) dry-heated
blet powder; and chromatograms of (F) RP (Ramipril) API and (G) AL
Table 2 Accuracy results [Recovery (%)] for the determina-
tion of AL (Amlodipine) and RP (Ramipril).
Compound Quantity (mg/mL)
Added Foundn Recovery (%) RSD (%)
RP 0.0792 0.0785 99.1 0.62
0.1008 0.1005 99.7 0.46
1.2010 1.2082 100.5 0.81
Average recovery 99.7 0.83
AL 0.1605 0.1613 100.5 0.50
0.1980 0.2005 101.3 0.53
0.2414 0.2408 99.8 0.57
Average recovery 100.5 0.79
nMean of three determinations for each concentration.
Table 3 Chromatographic parameter setting applied in the
robustness investigation.
Parameter Modiﬁcation Recovery (%) Number of
impurities
RP AL
pH 2.5 101.1 98.5 12
2.6 100.5 98.7 12
2.7 100.3 99.2 12
Flow rate
(mL/min)
0.9 99.9 99.3 12
1.0 100.5 98.7 12




50 100.2 99.0 12
55 100.5 98.7 12
60 100.3 99.5 12
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Fig. 2 (Ramipril impurity B, C, D, respectively, according to the
RRT) would stem from RP API. In addition to the known
impurities, the unknown impurities peaks numbered 2, 9, 10, 12,
13 originated in RP API. And the peaks numbered 1 (benzene
sulfonic acid), 3, 4(Amlodipine impurity D), 5 and 7 would
originate in AL besylate API. The stress test chromatograms of RP
and AL raw materials (Fig. 5) were also corresponding to the stress
test chromatogram of the tablet. A hypothesis may be made that
the purities of the raw materials of RP and AL may ultimately
affect the number and content of the related impurities in tablet
dosage forms.
3.2.4. Linearity and range
The linearity was checked by analyzing six working solutions of
RP over the concentrations range 0.01–0.25 mg/mL (0.01, 0.025,
0.05, 0.1, 0.125, 0.25 mg/mL) and 0.014–0.36 mg/mL (0.014,
0.036, 0.07, 0.14, 0.18, 0.36 mg/mL) for AL. The following
results were obtained: y¼44164xþ303.08 (r2¼0.9998) for RP,
and y¼37963x597 (r2¼0.9997) for AL, where y¼peak area,
x¼concentration of solution; r2¼ the square of determined corre-
lation coefﬁcient. The results indicated that the method was linear
over the concentration range studied.
3.2.5. Accuracy and precision
The accuracy of the method was assessed by recovery test.
A known amount of each standard powder was added to blank
sample composed of all the excipients equivalent to the ratio of the
tablet formulation, which was then mixed, extracted and subse-
quently diluted to yield three different concentrations of each
drug (0.08, 0.10 and 0.12 mg/mL for RP and 0.16, 0.20 and
0.24 mg/mL for AL besylate, n¼3). These samples were prepared
as described in Section 2.3 and analyzed as previously described.
The corresponding percentage recovery data are summarized in
Table 2.
Repeatability or intra-day precision was investigated by inject-
ing six replicate sample solutions on the same day. Inter-day
precision was assessed by analyzing newly prepared sample
solutions in triplicate over three consecutive days. Precision was
expressed as RSD value of the analyte peaks. RSD values obtained
for the peak areas of RP and AL on a single day (day 1, n¼6)
were 0.46% and 0.55%, respectively. RSD values on triplicate
injections on three successive days (days 1–3, n¼9) were 1.6%
and 1.8%, respectively. The results implied that the method
developed was accurate for the determination.
3.2.6. LOQ and LOD
The LOQs for RP and AL corresponding to a signal-to-noise ratio
of 10 were 0.2 mg/mL and 0.07 mg/mL for RP and AL, respec-
tively. And the LODs corresponding to a signal-to-noise ratio of 3
were 0.06 mg/mL and 0.02 mg/mL. The resultant RSD values for
these studies were r3.5% (n¼6).
3.2.7. Stability of solutions and robustness
The stability of the standard stock solutions was determined by
quantitatively determining each drug in different time comparing
to the response obtained for freshly prepared standard solutions.
No signiﬁcant changes (o2%) were observed according to the
chromatographic responses for the stock solutions stored at 4 1C
for two weeks, relative to freshly prepared standards. The stability
of sample solution was tested for every 2 h interval up to 12 h. TheRSD values of RP and AL were 1.2% and 1.0%, respectively. This
indicated that the sample solution was stable up to 12 h.
The robustness of the method was investigated by a small
variety of conditions including changes of pH of the eluent, ﬂow
rate and column temperature. The assay results for RP and AL by
three different analysts in the same laboratory were also investi-
gated. The RSD values did not exceed 2.5%. The degree of
reproducibility of the results obtained as a result of small
deliberate variations in the method parameters and by changing
analytical operators demonstrated that the method was robust, and
the data are summarized in Table 3.3.3. Assay of AL and RP in tablets
Three batches of compound tablets were analyzed using the
developed method. Satisfactory results were obtained that the
mean percentage found for RP and AL were in good agreement
with the label claimed. The mean percentage found and the RSD
values (Table 4) indicated that the proposed method could be
adopted for the determination of RP and AL in compound tablets.
Table 4 Assay results of AL (Amlodipine) and RP (Ramipril)
in compound tablets.
Batch number Foundn (%) RSD (%)
RP AL RP AL
B1 100.9 103.5 1.1 1.2
B2 98.28 101.1 0.95 0.93
B3 99.53 102.4 1.4 1.4
B1, B2, and B3 refer to three different batches.
nMean of three determinations.
S.-Y. Dai et al.4464. Conclusions
A gradient LC method has been developed and validated for the
analysis of RP and AL in tablet dosage forms. The results of the
stress testing revealed that the method was speciﬁc and selective.
The proposed method has the ability to separate the two main
components from their degradation products, related substances
found in tablet dosage forms and the tablet excipients. Therefore,
the chromatographic method can be used to analyze samples
obtained during accelerated stability experiments and routine assay
of RP and AL in combined tablet dosage forms. In addition, the
procedure can be further applied for the detection and determina-
tion of the related substances in tablets.References
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